Heart drug trial failures at Novartis and Novo Nordisk leave experts searching for answers

An experimental Novartis (NVS) drug designed to treat a genetic cause of heart disease has failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several similar medicines in clinical trials.
Despite cutting levels of the blood particle known as Lp(a) by 78 per cent, monthly doses of pelacarsen over nearly five years had no effect on preventing a second heart attack, stroke or the need for emergency procedures to unblock arteries, according to detailed results from the trial of more than 8,300 patients.
“Everybody in the world, me included, thought that this was going to work,” said Dr Steven Nissen of the Cleveland Clinic, who presented the data at the American Heart Association meeting in Chicago. “It didn’t do anything. It was completely neutral.”
Novartis and its co-developer Ionis Pharmaceuticals (IONS) announced in September that the drug had missed the trial’s primary goal, but investors and experts had been waiting for the full data to see whether it offered any benefit.
A second failed study, of a Novo Nordisk (NVO) drug aimed at heart inflammation, was also presented at the meeting. It hit its target of reducing inflammation but did not prevent major adverse cardiovascular events. Together, the results challenge some foundational theories about what drives heart disease.
High Lp(a) is a genetic risk factor affecting roughly 20 per cent of the global population, though few people know they have it, and no approved treatments exist. Researchers had hoped lowering it would yield benefits similar to statins, which sharply reduce the risk of heart attacks and strokes by cutting LDL cholesterol.
In the pelacarsen trial, patients received either a monthly 70mg dose or a placebo and were followed for a median of 4.7 years. All had previously suffered a major cardiovascular event, and other risk factors such as high LDL cholesterol and blood pressure were tightly controlled. About 20.6 per cent of patients on the drug stopped taking it because of adverse effects, compared with 7.5 per cent on placebo.
A separate statistical analysis published in NEJM Evidence examined several measures, including patients with a larger-than-average Lp(a) reduction after three months and only those who remained in the trial. It still showed no benefit.
Dr Donald Lloyd-Jones, a professor of cardiology at Boston University, said he would not recommend abandoning Lp(a) as a causal risk factor or therapeutic target until far more data were available from different patient populations.
Pelacarsen is an antisense oligonucleotide, a class of drug that reduces the production of proteins made by faulty genes. Rival candidates, including Amgen’s (AMGN) olpasiran and Eli Lilly’s (LLY) lepodisiran, use small interfering RNA and have lowered Lp(a) by about 95 per cent.
Nissen, who is leading the lepodisiran trial, said strong evidence remained that Lp(a) was a major cause of heart disease. He pointed to differences that could sway the outcome of future studies: pelacarsen was tested in patients who had already had a cardiovascular event, while the Lilly and Amgen trials include more people who have never had a heart attack or stroke. He added that siRNA drugs have proved better tolerated and more effective, but “whether that will translate into better outcomes remains to be seen”. Amgen expects Phase 3 results in early 2028 and Lilly in 2029.
Novo, best known for its GLP-1 diabetes and obesity drugs, announced in July that its ziltivekimab study had failed. The trial involved 6,300 patients with heart disease, advanced kidney disease and systemic inflammation. The drug, designed to neutralize the inflammatory protein interleukin-6, did not reduce the risk of death, heart attacks or strokes compared with a placebo, despite lowering inflammation as intended.
The result shocked many experts and dimmed Novo’s hopes of expanding beyond its blockbuster GLP-1 franchises. In September, the Danish group ended two other late-stage ziltivekimab trials in patients with heart failure and inflammation after an independent data monitoring committee concluded they were unlikely to succeed.
Dr Paul Ridker of Harvard’s Brigham and Women’s Hospital, a pioneer in explaining the link between inflammation and heart disease, suggested the drug may have been studied in patients whose disease was too advanced to respond, though he said targeting inflammation remained compelling. Dr Priscilla Hsue of UCLA, who was not involved in the study, agreed that the population was extremely sick and that inflammation might already have done its damage.
Lloyd-Jones said the similarly disappointing outcomes showed that “we need further trials using different compounds and different strategies”.